Related Experiment Video
Updated: Jul 5, 2026
06:58
A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
Published on: July 12, 2021
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy
Tomohide Abe1, Takayuki Seo, Takateru Ishitsu
1Division of Pharmacology and Therapeutics, Graduate School of Medical and Pharmaceutical Science, Kumamoto University, Kumamoto, Japan.
British Journal of Clinical Pharmacology
|May 21, 2008
Summary
This study found a link between a specific SCN1A gene polymorphism and carbamazepine resistance in epilepsy patients. This genetic variation may influence how well certain antiepileptic drugs work.
Area of Science:
- Genetics
- Neurology
- Pharmacology
Background:
- Epilepsy is a neurological disorder characterized by recurrent seizures.
- Antiepileptic drugs (AEDs) are the primary treatment, but drug resistance is common.
- Genetic factors are increasingly recognized as influencing AED response.
Purpose of the Study:
- To investigate the association between the SCN1A IVS5-91 G > A polymorphism and responsiveness to carbamazepine and phenytoin.
- To determine if this SCN1A gene variant impacts treatment outcomes in epileptic patients.
Main Methods:
- Genotyping of the SCN1A IVS5-91 G > A polymorphism in 228 Japanese epileptic patients.
- Logistic regression analysis to assess the association between the polymorphism and AED responsiveness.
- Adjustment for clinical factors influencing AED therapy outcomes.
Main Results:
- The AA genotype of the SCN1A IVS5-91 G > A polymorphism was significantly more frequent in carbamazepine-resistant patients (OR, 2.7; 95% CI, 1.1–7.1).
- A trend towards higher frequency of the AA genotype was observed in patients resistant to AEDs overall, though not statistically significant.
Conclusions:
- This study provides the first evidence linking the SCN1A IVS5-91 G > A polymorphism to carbamazepine-resistant epilepsy.
- The SCN1A gene polymorphism may play a role in predicting carbamazepine treatment efficacy.
- Further research is warranted to explore the implications of this genetic marker in epilepsy management.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...